33
total announcements
SENORES.NS · 15 min delayed
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to the 9th Annual General Meeting of the Company.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of 9th Annual General Meeting to be held on September 25, 2026.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting to be held on September 2, 2026, at Elara Capital Group in Mumbai.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding a copy of newspaper publication for the pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has announced the outcome of its Board Meeting held on August 26, 2026, where it approved several key decisions, including the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events or information. The company also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and proposed the incorporation of a Subsidiary Company in Canada to support its business and strategic objectives in the Canadian and other international markets.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the appointment of Mrs. Shilpa Sharma as Company Secretary & Compliance Officer, Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director, and the approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026. The company also proposed the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the outcome of its Board Meeting held on August 26, 2026, where it approved the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events or information and make disclosures to stock exchanges. The Board also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026, where the Board approved the appointment of Company Secretary and Compliance Officer, Non-Executive Additional Director, authorized officers for determining materiality of events, and approved the adoption of Employee Stock Option Scheme 2026 and proposed incorporation of Wholly Owned Subsidiary in Mexico and Subsidiary Company in Canada.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has announced the outcome of its Board Meeting held on August 26, 2026, where it approved several key decisions, including the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events or information. The company also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and proposed the incorporation of Wholly Owned Subsidiaries in Mexico and Canada to support its business and strategic objectives.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has announced the approval of various matters at its Board Meeting held on August 26, 2026, including the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers for determining materiality of events and disclosures. The company has also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and proposed the incorporation of Wholly Owned Subsidiaries in Mexico and Canada.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the appointment of Mr. Viranchi Arvindbhai Shah as Non-Executive Independent Director of the company, along with the appointment of Company Secretary and Compliance Officer, and other key decisions.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private Limited, Subsidiary of the Company from ICICI Bank Limited.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about the schedule of meet with analysts/institutional investors, to be held on August 25, 2026, at Antique Stock Broking Group in Mumbai.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has announced the outcome of its postal ballot, where shareholders have passed the ordinary and special resolutions with the requisite majority.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday, July 27, 2026 for Q1FY27.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has published unaudited financial results for the quarter ended June 30, 2026, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has made the audio recording of its earnings conference call for the quarter ended June 30, 2026, available on its website.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 for the quarter ended June 30, 2026, stating that there has been no deviation(s) or variation(s) in the utilization of funds raised through preferential issue of convertible equity warrants.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 for the quarter ended June 30, 2026. The company has confirmed that there has been no deviation(s) or variation(s) in the utilization of proceeds of IPO for the mentioned period. However, there is a delay in the going concern principle for investment in one of our subsidiaries, Havix, to fund deployment of capital of funds expenditure under requirements for setting up a manufacturing company facility for the production of sterile injections in our Atlanta facility.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations, detailing the utilization of IPO proceeds. The report indicates that there is an ongoing delay in implementation of one of the objects of the issue, which was scheduled to be completed by a Chartered Accountant.